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Abstract: Sp-family transcription factors are widely expressed in human tissues and involved in the regulation of many 
cellular processes and response to cellular microenvironment. These responses appear to be mediated by alterations in 
transcription factor affinity for DNA rather than altered protein level. How might such changes be effected? This review 
will identify the range of known post-translational modifications (PTMs) of Sp-factors and the sometimes conflicting lit-
erature about the roles of PTMs in regulating activity. We will speculate on the interaction between cell environment, 
chromatin microenvironment and the role of PTM in governing functionality of the proteins and the complexes to which 
they belong. 
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INTRODUCTION 
  The Sp/KLF family is divided into two major subgroups: 
the Sp-family, which are highly homologous to Sp1 in the 
zinc finger region; and the KLF family which are more het-
erogenous and are named after the Drosophila segmentation 
gene Kruppel which also contains 3 zinc finger motifs [1]. 
The Sp-family is made up of 8 genes Sp1-8, each located 
adjacent to a HOX gene cluster and the KLF family contains 
15 known members [2]. Specificity protein/Kruppel-like 
factor (Sp/KLF) family of transcriptions factors are charac-
terised by the presence of 3 highly conserved zinc finger 
domains which confer DNA-binding ability. Due to this con-
served DNA-binding motif, members of the Sp/KLF family 
share the same DNA recognition sites, namely GC 
(GGGGCGGGG) and GT (GGTGTGGGGG) boxes. The 
affinity of Sp/KLF proteins for these sites varies due to small 
amino acid sequence changes in the recognition domain. 
  The regulation of transcription by ubiquitously expressed 
transcription factors of this family is not generally thought to 
occur through protein turnover, thereby invoking a key role 
for post-translational modification of Sp proteins in govern-
ing transcriptional activity. 
The SP-Family 
  Sp1, the first identified member of this family [3, 4] was 
shown to be a transactivator of the simian virus 40 (SV40) 
early promoter [5, 6]. Since then seven further members of 
this family have been identified and were numbered Sp2-8, 
according to their order of discovery. The functional roles of 
the members of the Sp family have been investigated to vari-
able degrees with the most data having been collected for 
Sp1 and Sp3.  
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  Both Sp1 and Sp3 have been shown to exhibit ubiquitous 
expression, whereas Sp4 expression is restricted to brain and 
developing testis. Sp2 expression has been observed in a 
number of cell lines, however, no data is available regarding 
tissue expression levels [7]. Sp7 was identified as a bone 
specific transcription factor required for osteoblast differen-
tiation and bone formation [8]. The expression patterns of 
Sp5, Sp6 and Sp8 have yet to be investigated. The first four 
members of the Sp-family, Sp1-4, are more closely related to 
each other than to Sp5-8. Sp1-4 contain an N-terminal acti-
vation domain and a C-terminal DNA binding domain. Sp3 
also contains an inhibitory domain which is thought to medi-
ate suppression of Sp3 transcription activation. Sp3 is inac-
tive or only weakly active and is thought to act as a repressor 
for Sp1 activated genes by competing for the same binding 
sites [9]. Sp5-8 proteins are shorter, lacking the N-terminal 
activation domain of Sp1-4 which may explain their de-
creased transcription activation potential.  
  Little is known regarding the function of Sp5-8. The 
creation of knock out mice has provided some insight into 
the possible regulatory roles of Sp1-4. Sp1 null mice show 
severely retarded embryonic development and die after em-
bryonic day 10 (E10) [10]. This evidence indicates that Sp1 
is essential for normal embryonic development. Targeted 
homologous recombination of the Sp3 gene produced Sp
-/- 
embryos which exhibited late and impaired tooth and bone 
development. Sp3
-/- mice survived gestation, but died of res-
piratory failure perinatally [11]. These observations suggest 
that both Sp1 and Sp3 are involved in developmental regula-
tion of gene expression. Both Sp1 and Sp3 show increased 
expression in a number of cancers suggesting that these tran-
scription factors are switched back on during cancer cell 
differentiation. Virus particles are also known to ‘hijack’ 
Sp1/3 during viral replication and Sp1 appears to be a spe-
cific target of the SV40 virus. The function of Sp2 is poorly 
understood, however, it is clearly separate from the function 
of other Sp proteins as Sp2 preferentially binds GT boxes not 302    Current Genomics, 2008, Vol. 9, No. 5  Waby et al. 
GC boxes [7]. Sp2 overexpression has been noted in late 
stage human prostate tumours and may be oncogenic [12].  
  Sp4 knock out mice show a complex phenotype, different 
to that observed in Sp1 and Sp3 null mice. Sp4
-/- mice de-
velop normally until birth, however, within four weeks two 
thirds of pups die. The surviving Sp4
-/- mice exhibit retarded 
growth and males do not breed due to an absence of mount-
ing behaviour, which has been shown to be linked to brain 
abnormalities [13].  
  The Sp-family transcription factors appear to have di-
verse roles which require further characterisation. This is 
especially apparent for Sp5-8 proteins which are poorly un-
derstood. 
POST-TRANSLATIONAL MODIFICATIONS 
  Transcriptional control may be exerted via shutdown of 
Sp transcription factor translation, however such a crude 
method of transcriptional control would not be immediately 
effective as proteosomal degradation of proteins is not in-
stantaneous. A more refined method would be to modify 
reversibly Sp-family proteins in a manner which affects their 
efficacy. PTMs, provide a means of changing the protein 
structure to affect transcription without having to degrade or 
create  de novo transcription factor. There is a significant 
body of evidence for the post translational modification of 
Sp-family proteins in the form of phosphorylation, acetyla-
tion, glycosylation and sumolation. This evidence will be 
discussed here, however, as Sp1 and Sp3 are the best studied 
the majority of post translational modification data comes 
from these two family members. The high homology be-
tween Sp proteins, especially Sp1-4, suggests that roles of 
post translational modifications in the transcriptional control 
of one Sp member may also be relevant to others Sp pro-
teins. 
Phosphorylation 
  Phosphorylation appears to play a key role as a molecular 
‘on-off’ switch in a plethora of biological processes. There is 
a body of evidence to suggest a role for phosphorylation in 
transcription factor regulation. The initial suggestion that Sp-
family transcription factors were phosphorylated came in 
1990 from the observation that SV40 infection induced 
phosphorylation of Sp1 [14]. Since then, investigating the 
role of phosphorylation in Sp-family transcription factors has 
centred on the founder member. 
  The consensus of these studies appears to be that phos-
phorylation of Sp1 increases GC box affinity and facilitates 
transcriptional activation (see Tables). The precise mecha-
nism for this has yet to be revealed, however, the majority of 
phosphorylation sites thus identified in Sp1 are located 
within the DNA binding zinc finger domain, suggesting that 
phosphorylation produces a conformational change which 
facilitates DNA-zinc finger interaction.  
  Phosphorylation of Sp1 in response to viral infection has 
been reported in two further studies. Chun et al., reported 
that HIV-1 tat protein induces DNA-dependent kinase medi-
ated phosphorylation of human Sp1 at Ser131 [15]. A more 
recent study identified two specific sites in human Sp1 
(Ser56 and Ser101) which are hyperphosphorylated in re-
sponse to HSV-1 viral infection. This hyperphosphorylation 
requires the presence of a member of the phosphatidylinosi-
tol 3 -like kinase family, Ataxia telangiectasia mutated pro-
tein (ATM) [16]. There are multiple explanations for the 
enhanced phosphorylation state of Sp1 following viral infec-
tion. Firstly it is possible that phosphorylation may result in 
an increased DNA binding affinity, which could mediate 
viral “hijacking” of the transcriptional machinery. This 
would fit with the observed increase in activation of a HIV-1 
luciferase reporter construct following HIV-1 infection [15]. 
Conversely, enhanced Sp1 phosphorylation and DNA bind-
ing may be a protective effect to increase the transcription of 
‘cellular defence’ genes in the infected cell. Thirdly, Sp1 
increased GC-box binding may act to activate the apoptotic 
pathway and initiate death of infected cells. In support of 
this, Sp1 phosphorylation has been shown to activate RasL 
transcription [17]. However phosphorylation of Sp1 is obvi-
ously more complex than a simple on-off switch model as 
viral infection induced phosphorylation is reported to have 
either no effect or an activation effect on transcription [15, 
16].  
  Evidence regarding the role of phosphatases in Sp1 tran-
scriptional regulation is contradictory, however, the literature 
concurs that phosphatase proteins 1 and 2(A) are involved. 
The majority of evidence suggests that dephosphorylation of 
Sp1 causes a decrease in DNA binding and reduced tran-
scriptional activation, however a number of studies only in-
fer Sp1 dephosphorylation and do not specify the residues 
which are dephosphorylated [18-24]. Contradictory to the 
main body of evidence, PP2A inhibition with okadaic acid 
was shown to increase Sp1 Phosphorylation and HIV pro-
moter transcription with no observable effect on Sp1 DNA 
binding. PP2A dephosphorylation of Sp1 has also been re-
ported to increase the association of dephosphorylated Sp1 
with the chromatin fraction in a crude chromatin preparation 
[25]. Furthermore the dephosphorylation of Sp1 has been 
shown to increase Sp1 binding affinity to an inducible 
AAAT promoter element [18].  
  Although there appear to be exceptions, generally phos-
phorylation acts to increase DNA binding and transcriptional 
activation, whilst dephosphorylation has the opposite effect. 
The discrepancies between results may suggest further levels 
of transcriptional control, although the possibility cannot be 
excluded that the observations are experimental artefacts due 
to the different conditions used for the promoter assays. It is 
also possible that these contrasting data may reflect differing 
roles of phosphorylation in different cellular contexts. Fur-
ther work is required to clarify the role of transcription factor 
phosphorylation in viral infection and transcriptional control. 
Acetylation 
  The histone acetyl transferases (HATs) and histone 
deacetylases (HDACs) were originally named after their 
ability to introduce or remove acetyl groups (-CH3CHO) at 
lysine residues of histone proteins. It has since become clear 
that the function of these proteins is not restricted to his-
tones.  
  Site directed mutagenesis, coupled with an in vitro acety-
lation assay has demonstrated that Sp1 is acetylated at a sin-
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Table 1.  Phosphorylation of Sp Proteins 
DNA Binding  Transcription Effects 
Initiation Signal  Cell/Tissue 
Associated 
Kinase/  
Phosphatase 
Effect on  
Phosphorylation 
Including  
Residues/Location 
Probe/Assay Effect  Promoter 
Activation/ 
Repression 
Ref. 
SV40 infection  HeLa 
DNA dependent 
protein kinase 
Phosphorylation of 
Sp1 N-terminal 610aa 
(DNA binding domain 
and transcriptional 
activation domains) 
SV40 pro-
moter 
No change  -  -  [14] 
HIV-1 Tat protein  HeLa 
DNA dependent 
protein kinase 
Ser131 - - 
HIV1-
luciferase 
reporter 
construct 
Activation [15] 
Terminal differentia-
tion 
Rat liver tissue  Casein Kinase II 
Thr579 and additional 
sites in the C-terminus 
aa521-696 
Consensus 
Sp1 sequence 
10 fold de-
creased affinity 
- -  [49] 
Cyclin A 
NIH3T3 (mouse cell 
line) 
Cyclin A-Cyclin 
Dependant Kinase 
2 
Ser59 (corresponds to 
human Ser61) in N 
terminal 
DHFR pro-
moter frag-
ment 
Increased 
binding 
Hamster 
DHFR 
Activation [50] 
Cyclin A 
Mouse: U2OS 
(osteosarcoma); 3T6 
(embryonic fibro-
blast) 
CDK2 but CDC2 
not excluded 
Increased Sp1 phos-
phorylation at zinc 
finger domain 
Murine TK 
promoter 
Increase both 
sp1 and sp3 
consensus 
Sp1 site used 
in a luciferase 
assay 
Activation [51] 
 
Human fibrosar-
coma and human 
renal carcinoma cell 
lines 
Atypical protein 
kinase C, PKC- 
Overexpression of 
PKC- increases SP1 
phosphorylation 
- - 
VPF/VEGF 
promoter 
luciferase 
reporter 
construct 
Activation2-
4 fold 
increased 
expression 
[52] 
CAM induced 
apoptosis 
WKY12-22 and 
WKY3M-22 (rat 
aortic smooth mus-
cle cells) 
Atypical protein 
kinase C, PKC- 
Phosphorylates Sp1 
FasL pro-
moter 
Increased 
phosphorylated 
Sp1 binding 
FasL promo-
ter luciferase 
reporter 
construct 
Activation [17] 
Angiogenin II 
WKY12-22 (rat 
aortic smooth mus-
cle cells) 
Atypical protein 
kinase C, PKC- 
Thr668, Ser670, and 
Thr681 in zinc finger 
domain 
ChIP 
p676/686 Sp1 
Increased 
binding at 
platelet-
derived growth 
factor-D pro-
moter 
Platelet-
derived 
growth 
factor-D 
Activation [48] 
P42/p44 MAPK 
stimulation using 
estradiol-inducible 
raf-1 CCL39 cells 
CCL39 hamster 
fibroblast (for 
EMSA), SL2 Dro-
sophila (for pro-
moter assays) 
P42/p44 MAPK 
Thr453 (Glutamine 
rich transactivating 
domain) and Thr739 
(C-terminal D do-
main) in vitro and in 
vivo 
Human 
VEGF pro-
moter 
Increased 
recruitment to 
promoter 
Human 
VEGF pro-
moter 
Activation [53] 
HSV-1 viral infec-
tion 
Hela; HFF2 (immor-
talised human fore-
skin fibroblasts) 
Ataxia telangiecta-
sia mutated protein 
(ATM) 
hyperphosphorylates 
Ser-56 and Ser-101 
-  -  CAT assay  No Change  [16] 
- 
CCRF-CEM a 
human T-cell leu-
kaemia line and its 
antifolate resistant 
sublines 
? 
Nuclear proteins 
purified from antifo-
late resistant cells 
contained 8 fold more 
phosphor Sp1 
GC box 
consensus 
sequence 
Dramatic loss 
of binding 
Reduced 
folate carrier 
(RFC) 
Reduced 
expression 
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(Table 1) contd…. 
DNA Binding  Transcription Effects 
Initiation Signal  Cell/Tissue 
Associated 
Kinase/  
Phosphatase 
Effect on  
Phosphorylation  
Including  
Residues/Location 
Probe/Assay Effect  Promoter 
Activation/ 
Repression 
Ref. 
Glutaminase 
antisense RNA 
EATC Erlich tumor 
cells 
? 
3 fold increase in Sp1 
phosphorylation 
Sp1 consen-
sus 
Inhibition of 
Sp1–DNA 
binding 
Luciferase 
reporter 
construct 
containing 
Sp1 consen-
sus ans 
TATA box 
Activation [55] 
Noglamycin  
treatment 
WKY12-22 (rat 
aortic smooth 
muscle cells) 
PKC- 
Induced Sp1 phosphory-
lation 
Sp1/Sp3 
consensus 
sequence 
Increased Sp1 
binding 
Platelet 
derived 
growth factor 
B chain 
Activation [56] 
Scleroderma Human  fibroblasts  ? 
Dermal fibroblasts from 
patients with Scleroderma 
show an increased level 
of Sp1 phosphorylation 
with no observed differ-
ence in overall Sp1 levels 
this increased phosphory-
lation is associated with 
increased expression of 
the alpha2(I) gene 
- - -  -  [57] 
Okadaic acid  
stimulation  
(PP2A inhibitor) 
Lymphoblastoid 
Tcell line 
PP2A? 
OKA treatment resulted 
in Sp1 phosphorylation 
HIV pro-
moter 
No change  HIV promoter  Activation  [58] 
T-cell receptor 
stimulation (TCR) 
Human T-cells 
PP1 and PP2 
INHIBITION by 
calculin A or 
okadaic acid 
Blockade of PP1 and PP2 
increased Sp1 phosphory-
lation 
IL-21R 
promoter 
Decreased 
Real time 
PCR quantifi-
cation of IL-
21R mRNA 
levels 
Reduced 
TCR-
induced IL-
21R expres-
sion 
[59] 
Glucose 
30A5 (mouse 
preadipocytes) 
PP1 - 
Acetyl-CoA 
carboxylase 
promoter II 
Decrease 
Acetyl-CoA 
carboxylase 
promoter II 
Repression [19] 
Glucose Hepatoma  cells  PP1  - 
Aldolase and 
pyruvate 
kinase pro-
moters 
Decrease 
Aldolase and 
pyruvate 
kinase pro-
moters 
Repression [20] 
Mp1 ligand  
(thrombopoietin) 
Y10/L8057 (mega-
karyocytic cells) 
PP1  -  Cyclin  D3 Decrease Cyclin  D3  Repression  [21] 
Lysophosphatidyl-
choline 
HUVEC PP2A  - 
Nitric-oxide 
synthase 
Decrease 
Sp1 consen-
sus 
Repression [23] 
Adipocyte differ-
entiation 
3T3-L1  
preadipocyte 
? 
Dephosphorylation of 
Sp1 
Amino acid 
adipocyte 
transporter 
(AAAT) 
promotor 
Increased 
binding 
- -  [18] 
CD2/CD28  
costimulation 
Human T lympho-
cytes, 
Kit225 cells 
PP2A 
Dephosphorylation of 
Sp1 
HIV-1 LTR 3 
Sp motif 
Decrease 
SV40 early 
promoter, 
HIV-1 LTR 
Repression [22] Post-Translational Control of Sp-Family Transcription Factors  Current Genomics, 2008, Vol. 9, No. 5    305 
(Table 1) contd…. 
DNA Binding  Transcription Effects 
Initiation Signal  Cell/Tissue 
Associated 
Kinase/  
Phosphatase 
Effect on  
Phosphorylation 
Including  
Residues/Location 
Probe/Assay Effect  Promoter 
Activation/ 
Repression 
Ref. 
Lipopolysaccharide 
(LPS) insult 
Mouse lung  ? 
Dephosphorylation at 
serine and threonine 
residues and phos-
phorylation at a 
tyrosine residue 
Sp1 consen-
sus 
Decreased 
binding 
- -  [24] 
Cell cycle interphase 
Human cell lines 
and T cells 
PP2A 
Dephosphorylation at 
Ser59, and Thr681 
Cell lysis and 
analysis of 
chromatin 
containing 
fraction 
Increased 
association of 
dephosphory-
lated Sp1 with 
chromatin 
- -  [25] 
In vitro treatment of 
nuclear extracts with 
dephosphotase 
HT29 - 
Inferred decreased Sp 
phosphorylation 
AKR1C1 
promoter 
Decrease -  -  [60] 
 
lated using pan-acetyl antibodies [27]. Mutation of a lysine 
residue in the Sp3 inhibitory domain can dramatically reduce 
but not abolish Sp3 acetylation, indicating that Sp3 is acety-
lated at further lysine residues [27]. Our data (Waby, 
Chirakkal & Corfe unpublished) indicate that the long form 
of Sp3 is the actylated form and the shortform is not acety-
lated, possibly suggesting a role for N-terminal acetylation in 
Sp3 regulation, at least in colorectal cells. 
  Whilst it is evident that both Sp1 and Sp3 are acetylated 
in vivo, the functional relevance of this is unclear. Treatment 
of cells with the HDAC inhibitor trichostatin A (TSA) has 
been shown to increase Sp1 acetylation levels resulting in 
increased expression of the TGF beta type II receptor [28]. 
Specific silencing of each of HDAC1, HDAC2 or HDAC3 
using siRNA resulted in increased p21 promoter activity and 
expression in an Sp3-dependent manner, suggesting that in-
creased acetylation caused increased activation of Sp3 con-
trolled genes [29]. In support of a role for acetylation in 
Sp1/3 transactivation, increased acetylation of Sp1 by the 
DNA topoisomerase II poison TAS causes increased GC-box 
dependent transcription in MCF7 cells [30]. 
  However, recent work has cast doubt upon this simplistic 
‘more acetylation = more transcription’ model. Expression of 
a recombinant K703A Sp1, which cannot be acetylated at 
lysine 703, leads to increased expression of the 12(s)–
lipoxygenase gene [26]. Treatment with the HDAC inhibi-
tors has also been shown to attenuate the expression of cy-
cloxygenase 2 (COX-2) and insulin like growth factor bind-
ing protein 3 (IGFBP3) [31, 32]. One possible explanation 
for these apparently contrasting data, may reside in the fact 
that Sp1 and Sp3 compete for GC-box binding sites, this 
competition could potentially be swayed by acetylation 
modifications. Sp3 is normally a poor transcriptional activa-
tor, however, recombinant Sp3, expressed in a system which 
lacks acetyltransferases, was found to act as a transcriptional 
activator with similar potency to Sp1 [33]. This hypothesis is 
further supported by the observation that GAL4-Sp3 but not 
GAL4-Sp1 is able to induce p21 in a TSA-dependant man-
ner, indicating that the acetylation of Sp3 is important [34]. 
  Transcription factor activity can also be modulated by 
altered affinity to the binding site. Again, as Sp1 and Sp3 
compete for GC-boxes, small alterations in binding affinity 
could result in altered occupancy at the promoter and alter 
the gene expression according to whether the resident tran-
scription factor is an activator or repressor. Chromatin im-
munoprecipitation (ChIP) assays have demonstrated a reduc-
tion in binding of Sp1 accompanied by an increase in Sp3 
binding at the major vault protein (MVP) promoter following 
treatment with either TSA or butyrate [35]. A similar switch 
of Sp1 for SP3 has been observed at the promoter for the 
pro-apoptotic protein BAK following butyrate treatment 
[36]. 
  In summary, acetylation of Sp1/3 has profound effects 
upon gene transcription. These effects seem to be exerted 
through a combination of altered binding affinity and 
changes in transactivation potential which alter the balance 
between Sp1 activation and Sp3 repression.  
Glycosylation 
  Glycosylation has long been recognised as a PTM of 
transcription factors associated with regulation of activity 
[37]. Glycosylation of Sp1 is most widely studied in regula-
tion of glucose-responsive genes stimulated by deprivation 
or through insulin response pathways. Goldberg et al. (2006) 
reported glycosylation of Sp1 altered transcriptional activity 
of Sp1 in glomerular mesangial cells at the PAI-1 promoter 
[38]. Sp1 became glycosylated in high-glucose conditions. 
This did not appear to alter the binding affinity for the pro-
moter by EMSA but was associated with increased transcrip-
tional activity of PAI-1. Contrastingly, Sp1 was downregu-
lated by by glucose inhibition in HeLa cells. In this cell line 
and context the glycosylation of Sp1 was shown to be recip-
rocal with threonine phosphorylation [39]. In addition to 
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Table 2.  Other Post Translational Modifications of Sp Proteins 
Acetylation 
DNA Binding  Transcription Effects 
Treatment Cell/Tissue 
Associated 
HAT/HDAC 
Effect on  
Acetylation  
Including  
Residues/Location 
Probe/Assay Effect  Promoter 
Activation/ 
Repression 
Ref. 
   P300/  HDAC1 Sp1  K703  -  - 
In vitro BCAT-
2 reporter  
transcription 
assay (using 
Hela nuclear 
extract)- 
Activation- [27] 
Trichostatin A  
(TSA)  
treatment- 
MCF-7L breast 
cancer cell lineHela 
and SL2 Drosophila 
cells 
Both Sp1 and Sp3 
associate with 
HDAC1 and 
p300P300 and 
CBP (braun 2001) 
 
TSA is a HDAC inhibitor 
and therefore would be 
expected to increase Sp1/3 
actetylation, however, this is 
not shown directlySp3 
inhibitory domain lysine is 
acetylated and acts as a 
repressor, Sp3 purified from 
transfected insect cells lacks 
this acetylation and acts as a 
transcriptional activator 
EMSA using 
Sp1 consen-
sus sequence; 
ChIP 
No change 
in Sp1/Sp3 
binding 
RII promoter 
luciferase 
reporter con-
struct trans-
fected into cells 
TSA treatment 
enhanced 
activity 
[61] 
- 
MCF-7 (T5) cell 
lysate 
HDAC1 and 
HDAC2 are 
associated with 
Sp1 and 
Sp3HDAC2 
(davie 2003 Nutr 
prot in cancer 
prevention) 
- -  -  -  -  [62] 
TSA 
MIA PaCa-2 pancre-
atic cancer cells 
Sp1 forms a 
multiprotein 
complex with NF-
Y, P300, PCAF 
and HDAC1 
TSA treatment enhanced the 
acetylation of Sp1 
- - 
TRII promoter 
luciferase 
construct 
Activation [28] 
TAS-103  
treatment 
Human epidermoid 
cancer KB cells; 
Human glioblastoma 
T98G cells; MCF-7 
breast cancer cells 
P300  Acetylation of Sp1  -  -  SV40 promoter  Activation  [30] 
Phorbol  
12-myristate  
13-acetate  
(PMA) 
Human epidermoid 
carcinoma A431 
cells 
HDAC1;  p300 
Sp1 is acetylated at K703 
and is deacetylated upon 
PMA treatment 
- - 
12(S)-
lipoxygenase 
promoter -
luciferase 
reporter con-
struct 
Mutant K703A 
Sp1 (deacety-
lated) showed 
reduced acti-
vation capacity 
[26] 
Butyrate  
treatment 
Caco-2 cells  P300  Sp3 acetylation 
GC box from 
the hIGFBP-
3 promoter 
Increased 
binding of 
acetylated 
Sp3 
hIGFBP-3 
mRNA levels 
Repression [31] 
Butyrate  
treatment 
HCT116 cells  - 
Acetylation of Sp1 reduces 
binding, increased Sp3 
binding 
EMSA -  BAK  Activation  [36] Post-Translational Control of Sp-Family Transcription Factors  Current Genomics, 2008, Vol. 9, No. 5    307 
(Table 2) contd…. 
Glycosylation 
DNA Binding  Transcription Effects 
Treatment Cell/Tissue 
Interacting  
Proteins 
PTM Including 
Residues/ 
Location  Probe/Assay Effect  Promoter 
Activation/ 
Repression 
Ref. 
Wheatgerm agglu-
tinin (WGA) 
binding of glyscoy-
lated Sp1 
Hela cell nuclear 
extracts 
- 
Glycosylation at 
Sp1 Ser-
ine/Threonine 
residues 
DNAse I pro-
tein experi-
ments 
No effect 
on DNA 
binding 
SV40 
Decreased transcrip-
tion 3-4 fold 
[37] 
Under glucose 
starvation, cAMP 
stimulation with 
forskolin treat-
ment, results in 
nearly complete 
deglycosylation of 
Sp1. 
NRK cells  - 
Sp1 deglycosyla-
tion, leading to 
proteosome target-
ing 
EMSA using an 
Sp1 consensus 
sequence 
Virtual loss 
of DNA 
binding 
activity 
- -  [63] 
Mutation of a 
glycosylation site 
in a fragment of 
Sp1 
Hela - 
Mutation of the 
glycosylation site 
should cause degly-
cosylation of the 
Sp1 fragment 
- - 
Gal4 depend-
ant luciferase 
reporter con-
struct 
Activation with both 
mutant and wild type 
Sp1 fragments. How-
ever in an in vitro 
assay only the glyco-
sylated form could 
bind to TAF-110 
[43] 
Glycolysis inhibi-
tion by 2-DG (non 
metabolizable 
glucose analogue) 
Hela -  - 
HPV18 URR 
Sp1 binding 
sequence 
No effect 
on DNA 
binding 
Luciferase 
reporter assay 
Repression [39] 
Glutamine or 
glucosamine 
treatment 
Caco-2 - 
Increased O-
glycosylation of Sp1 
leading to its trans-
location into nu-
cleus 
GC boxes of 
the ASS pro-
moter used as a 
probe for 
EMSA 
Increased 
binding 
- -  [40] 
Insulin treatment 
H-411E rat  
hepatoma cell line 
Drosophila SL2 cells 
used for reporter 
assay 
- 
Increased total and 
O-GlcNAc-
modified Sp1 pri-
marily in the nu-
cleus and induced 
CaM I gene tran-
scription 
- - 
Cotransfection 
of Sp1 and rat 
CaM I pro-
moter contain-
ing Sp1 sites 
in SL2 cells 
Activation 
[41, 
64] 
Glucose depriva-
tion or treatment of 
cells with 6-diazo-
5-oxo-L-norleucine 
NB4 cells  - 
Deglycosylation of 
Sp1 
ChIP for 
hTERT pro-
moter 
No effect 
qRT-PCR for 
hTERT gene 
No effect on transcrip-
tion 
[44] 
Insulin treatment 
H-411E rat hepatoma 
cell line 
 
- 
Glycosylation 
followed by phos-
phorylation at 
Serines 613, 642, 
699, 703 and 
threonine 641. 
- -  CaM  I  mRNA 
Levels of CaM I 
mRNA increased 
steadily with time 
following insulin 
exposure 
[42] 
High glucose 
Glomerular mesan-
gial cells 
- 
Glycosylation of 
Sp1 
PAI-1 promoter 
used in EMSA 
No effect 
on DNA 
binding 
PAI-1 pro-
moter 
Activation [38] 
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(Table 2) contd…. 
Sumoylation 
DNA Binding  Transcription Effects 
Sp-Protein 
 
Cell/Tissue 
Interacting 
Proteins 
PTM Including  
Residues/ 
Location  Probe/Assay Effect  Promoter 
Activation/ 
Repression 
Ref. 
Sp3 MCF-7E   
Sp3 and it’s 
shorter isoforms 
(M1 and M2) are 
sumolyated at 
K551 
  
PSA  
promoter 
K551R substitution led to a marginal increase 
of transactivation for full length Sp1. 
The same substitution in the M1 isoform 
markedly enhanced transactivation 
[46] 
Sp1 MCF-7E   
Sp1 is sumolated 
at K16, governing 
processing 
- - 
Synthetic,  
p21 
Sumolation of Sp1 is repressive of transcrip-
tion 
[45] 
Sp3 SW480      -  - 
SRC-1A  
promoter 
Differential according to isoform  [47] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Alignment of Sp-family DNA binding Zinc finger domains. Shaded residue = known post translational modification g= Glycosyla-
tion; a=Acetylation sites; p=Phosphorylation sites (nb ser670 and thr668 inferred from rat data). *=conserved residue.  
glycosylation has been implicated in the shuttling of Sp1 
between nucleus and cytoplasm, a further mechanism of 
regulation analogous to NFkB. Brasse-Hagnel et al. (2003) 
demonstrated that upregulation of arginosuccinate synthetase 
by both glutamine and glucosamine was associated with gly-
cosylation of Sp1 in the cytosol and subsequent translocation 
to the nucleus for binding to the ASS promoter [40]. A simi-
lar observation was made by Majumdar et al. (2003) who 
identified cytosolic glycosylation of Sp1 in H-411E rat hepa-
toma cell lines underwrote translocation to the nucleus and 
activation of calmodulin transcription in response to insulin 
(but not glucagon) [41]. In an elegant follow-up study the 
same group identified sequential and reciprocal glycosyla-
tion of Sp1 following insulin treatment of cells. Sp1 was 
glycosylated in the cytosol, but this appeared to be a tran-
sient effect which was subsequently replaced by phosphory-
lation. The reciprocity of serine/threonine phosphorylation 
observed by Kang et al. (2003) was elucidated by Majumdar 
as replacement of glycosylation by phosphorylation at the 
following sites: serine 613, 642,699, 703 and threonine 641 
[42]. 
  Glycosylation of Sp1 has also been implicated in the 
regulation of protein-protein interactions. Roos et al. (1997) 
used a glycosylated or unglycosylated fragment of Sp1 (SpE 
aa378-495) to show that binding to TAF-110 and Sp1 was 
blocked by glycosylation in this region [43]. Further con-
flicting data over the role of glycosylation was provided by 
Chou et al. who showed that arsenic-responsive gene expres-
sion is modulated through and Sp1 response. This was asso-
ciated with altered glycosylation, but glycosylation of Sp1 
alone was insufficient to drive expression of an arsenic re-
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  Taken together, the data suggest that glycosylation has a 
potentially important role in the wider regulation of Sp1 
through governing its cellular location and potentially regu-
lating its binding to co-factors. The data seem to suggest that 
beyond this level, glycosylation may be replaced by phos-
phorylation as the key regulator of transcriptional activity at 
the promoter level. 
Sumoylation 
  SUMO (small ubiquitin-like modifier) is a PTM of pro-
teins occurring at lysines within a recognised motif: I/V-K-
X-E. SUMO-1 adds 9kDa to proteins following modifica-
tion; SUMO2 and 3 may polymerise and thereby add more 
mass. Sumoylation is implicated in the regulation of protein-
protein interactions, cellular localisation and has been impli-
cated in regulation of a number of transcription factors as 
both activator and repressor. 
  Sumoylation has been observed in both Sp1 and Sp3 [45, 
46]. Using MCF-7E cells Spengler et al. (2005) showed that 
Sp3 and its shorter isoforms (M1, M2) were modified by 
SUMO through a combination of immunoprecipitaion and 
overexpression analyses. Their predictions suggested that 
Sp3 has three potential sumoylation sites: K9, K120 and 
K551. Site directed mutagenesis identified K551 as the af-
fected residue in Sp3. K551R substitutions made in full-
length Sp3 led to only a marginal increase in transactivation 
of the PSA promoter (ibid.). In contrast the same mutation in 
the M1 isoform led to a markedly enhanced transactivation 
activity. This finding was consolidated with a similar study 
examining the roles of Sp3 isoform sumoylation on transac-
tivation of the SRC-1A promoter [47].  
  There are fewer reports of the effect of sumoylation on 
Sp1 activity. Spengler and Brattain followed up their Sp3 
analysis with identification of sumoylation of Sp1 at K16. 
The sumoylation is also associated with activation but 
through enhanced proteolytic cleavage of the inhibitory do-
main at the N-terminus of Sp1 leading to activation [45].  
  Clearly there is potential for several members of the Sp1 
family to be regulated via  sumoylation, but no consistent 
picture emerges: for Sp3 effects are isoforms-specific and 
the known sumoylation site of Sp3 is absent from Sp1. In 
Sp1 sumoylation regulates other post-translational modifica-
tion (proteolytic cleavage) which in turn is activating. 
SUMMARY & FUTURE WORK 
  This review has highlighted the need for further research 
in this area. Research thus far has been restricted to the 
founder family member Sp1 with some attention paid to Sp3. 
However, the majority of PTMs identified are restricted to 
the highly conserved DNA binding domain which suggests 
that as these residues are conserved within the Sp family, the 
PTMs identified for Sp1 and Sp3 may also apply to other Sp 
proteins. The mechanism of action for these PTMs has yet to 
be discovered, however the observation of a high density of 
PTMs in the DNA binding domain suggests that PTMs could 
act to structurally alter the zinc fingers to increase or de-
crease DNA binding affinity. PTMs which are located within 
the DNA binding face of the protein may be more difficult to 
identify and most certainly will be unable to be purified us-
ing ChIP. However, a recent study by Tan et al. was able to 
ChIP phosphorylated Sp1 suggesting that in some cases the 
phosphorylation is not present in the DNA binding face but 
may facilitate a conformational change which affects binding 
efficiency [48]. 
  The observed reciprocity between glycosylation and 
phosphorylation suggests that post-translation control may 
not be as simple as PTMs acting as switches. It seems likely 
that combinations of phosphorylation, acetylation, sumoyla-
tion cooperate to produce subtle changes in transcriptional 
activation, possibly acting more like a rheostat than a binary 
switch. Future work will need to examine the combinations 
of effects of PTMs on binding. A further, as yet unexplored 
area is the effect of local chromatin architecture and whether 
the same combinations of PTMs in the same cell may have 
distinct effects on activity at different chromosomal loci. 
Addressing these questions will require state-of-the-art 
chromatin immunoprecipitation approaches.  
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